Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Georgetown Translational Pharmaceuticals
USA
- Ownership
- Private
- Development stage
- Other
01
Overview
GTP developed late-stage and close-to-market improved treatments for central nervous system diseases. Its lead programs included Pain Brake for neuropathic pain (NDA submission planned within ~18 months as of mid-2017), GTP-004 for myasthenia gravis with reduced GI side effects compared to standard therapy, and GTP-011 for motion sickness in elderly patients. The company was acquired by Oxis International in mid-late 2017; its assets became part of GT Biopharma’s broader pipeline that also includes oncology immunotherapies.[1][3][6]
- Therapeutic areas
- Neurology
- Modalities
- Small moleculesRepurposed drugsCombination therapy
- Industry
- Biotech
02
Partnerships
Oxis International Inc./GT Biopharma Inc.
Beyond the preview
Go deeper on Georgetown Translational Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Georgetown Translational Pharmaceuticals.